Brief: Aim Immunotech announces commencement of Phase 2 study of Ampligen® for the treatment of pancreatic cancer
18/08/2022 14:07
Aug 18 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES COMMENCEMENT OF PHASE 2 STUDY OF
AMPLIGEN® FOR THE TREATMENT OF PANCREATIC CANCER
* AIM IMMUNOTECH INC - COMPANY RECEIVES IRB APPROVAL OF
STUDY
PROTOCOL
* AIM IMMUNOTECH INC - EXPECT STUDY SITES TO BE OPEN AND
RECRUITING PATIENTS IN LATE Q3/EARLY Q4 OF 2022
Source text for Eikon: ID:nGNX3kKDdH
Further company coverage: AIM.A
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential